Overall, our study highlights that TIM3/Galectin-9 pathway plays an essential role in CD8+TILs exhaustion and the immune escape of DLBCL, and is a valuable prognosticator and can facilitate the development of novel immunotherapy. The gene discussed is HAVCR2; the disease is diffuse large B-cell lymphoma.